Unlike the observation with SLFN11, SLFN12 expression is correlated with endocrine therapy sensitivity in estrogen-positive breast cancer, as SLFN12 is one of the 60 differentially methylated region (DMR) genes in breast cancers with endocrine resistance. The gene discussed is SLFN11; the disease is breast carcinoma.